Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAlvaro J. AlencarUniversity of MiamiMXMei XueTianjin University of Science and TechnologyYDYuan DongCentral University of Finance and Economics

Discussion

Loading...

Member takes

Overview

Retrospective study shows healthcare resource utilization patterns in mantle cell lymphoma, indicating increased bendamustine and venetoclax use.

Key Points

  • This study evaluates real-world treatment patterns and healthcare resource utilization in patients with mantle cell lymphoma.
  • Retrospective observational study using Symphony Integrated Dataverse®
  • Patients who initiated MCL treatment from Jan 2020 to Apr 2025 were included
  • Treatment regimens categorized into groups such as bendamustine and venetoclax
  • Time to discontinuation and next treatment calculated across lines of therapy
  • 5989 MCL patients initiated first-line treatment, with common regimens including bendamustine
  • Healthcare resource utilization was highest for R-CHOP and B-based chemotherapy
  • BTKi use increased across lines of therapy, while chemotherapy utilization decreased

Cite This Study

Alencar et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc35https://doi.org/10.1182/blood-2025-8020
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States2025
  2. 2Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States2025
  3. 3Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States2025
  4. 4Navigating the post–covalent bruton tyrosine kinase inhibitor (cBTKi) landscape in mantle cell lymphoma (MCL): Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization (HCRU).2026
  5. 5Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study2025 · 1 citations